Comparing Peak Bio (PKBO) & Its Peers

Peak Bio (NASDAQ:PKBO) is one of 295 public companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its competitors? We will compare Peak Bio to similar businesses based on the strength of its valuation, institutional ownership, profitability, dividends, risk, analyst recommendations and earnings.

Institutional & Insider Ownership

50.5% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 19.9% of Peak Bio shares are held by insiders. Comparatively, 15.9% of shares of all “Biological products, except diagnostic” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Peak Bio has a beta of 1.56, indicating that its share price is 56% more volatile than the S&P 500. Comparatively, Peak Bio’s competitors have a beta of 1.14, indicating that their average share price is 14% more volatile than the S&P 500.

Profitability

This table compares Peak Bio and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Peak Bio	N/A	N/A	-253.92%
Peak Bio Competitors	-4,956.17%	-159.22%	-42.94%

Earnings and Valuation

This table compares Peak Bio and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Peak Bio	$370,000.00	-$12.83 million	-0.33
Peak Bio Competitors	$545.94 million	-$37.35 million	-21,558.70

Peak Bio’s competitors have higher revenue, but lower earnings than Peak Bio. Peak Bio is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a summary of current ratings and target prices for Peak Bio and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Peak Bio	0	0	0	0	N/A
Peak Bio Competitors	1696	4985	12973	252	2.59

As a group, “Biological products, except diagnostic” companies have a potential upside of 61.37%. Given Peak Bio’s competitors higher possible upside, analysts plainly believe Peak Bio has less favorable growth aspects than its competitors.

Summary

Peak Bio beats its competitors on 6 of the 10 factors compared.

About Peak Bio

Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of patients with inflammatory, cancer, and rare and specialty diseases. The company's lead product candidate is PHP-303, which is in phase 2 clinical study for the treatment of alpha-1 antitrypsin deficiency and acute respiratory distress syndrome. It also develops Trop2 PH1, an antibody-drug-conjugate for solid tumors. The company was founded in 2020 and is based in Pleasanton, California.